GAP Supply Act

The GAP Supply Act (HR7528) was introduced in the House of Representatives on February 12, 2026, by Rep. Carter of Georgia and subsequently referred to the House Committee on Energy and Commerce. This bill proposes to amend section 503B of the Federal Food, Drug, and Cosmetic Act by extending the period outsourcing facilities can supply drugs during shortages by 180 days. This regulatory adjustment is intended to enhance the ability of these facilities to mitigate drug shortages. This bill does not authorize or appropriate any specific funding amount. Its mechanism is regulatory relief, providing a 'tail period' for outsourcing facilities to continue compounding and distributing drugs when a shortage is declared. This directly benefits pharmaceutical manufacturers and distributors by offering a more consistent supply chain and reducing potential disruptions during drug shortages. The bill's impact is structural, aiming to improve the operational flexibility of the pharmaceutical supply chain rather than providing direct financial incentives. Companies like Pfizer Inc. ($PFE), Johnson & Johnson ($JNJ), Merck & Co., Inc. ($MRK), Amgen Inc. ($AMGN), Gilead Sciences, Inc. ($GILD), and Viatris Inc. ($VTRS) operate within the pharmaceutical sector and could experience indirect benefits from a more stable drug supply chain. A consistent supply reduces the risk of production halts or delays due to shortages, which can impact revenue and operational efficiency. However, the bill is in an early stage of the legislative process, having only been introduced and referred to committee. Recent market data for these companies shows varied performance. Over the last 7 days, $PFE is down 3.28%, $JNJ is down 2.19%, $MRK is down 1.87%, $AMGN is down 3.88%, $GILD is down 0.56%, and $VTRS is down 2.07%. Over the last 30 days, $PFE is up 0.41%, $JNJ is down 0.55%, $MRK is up 1.94%, $AMGN is down 8.48%, $GILD is down 3.71%, and $VTRS is down 6.57%. These movements reflect broader market dynamics and company-specific news, not direct reactions to this early-stage bill. The next legislative steps involve committee consideration, potential hearings, and a committee vote before it can proceed to a full House vote. Given its early stage and regulatory nature, the immediate market impact is minimal. The bill's sponsor, Rep. Carter, is a Republican from Georgia, and its referral to the House Committee on Energy and Commerce indicates it will undergo scrutiny within a relevant committee. The legislative process for such a bill can be lengthy, and its ultimate passage is not guaranteed.